Prima BioMed (NASDAQ:IMMP) Stock Price Passes Below 50 Day Moving Average – Time to Sell?

Shares of Prima BioMed Ltd (NASDAQ:IMMP) passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $0.44 and traded as low as $0.3925. Prima BioMed shares last traded at $0.4169, with a volume of 660,523 shares trading hands.

Analyst Ratings Changes

A number of equities research analysts recently commented on IMMP shares. Robert W. Baird cut Prima BioMed from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $7.00 to $1.00 in a research note on Friday, March 13th. Citizens Jmp lowered Prima BioMed from an “outperform” rating to a “market perform” rating in a research note on Friday, March 13th. Wall Street Zen upgraded Prima BioMed to a “hold” rating in a report on Saturday, April 18th. Finally, Maxim Group upgraded Prima BioMed from a “hold” rating to a “buy” rating in a research report on Wednesday, June 17th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $5.50.

Prima BioMed Trading Up 2.3%

The business’s 50-day moving average price is $0.44 and its two-hundred day moving average price is $1.55.

Institutional Trading of Prima BioMed

An institutional investor recently raised its stake in Prima BioMed stock. Jane Street Group LLC boosted its holdings in shares of Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 51,574 shares of the biotechnology company’s stock after acquiring an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 2.32% of the company’s stock.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.